ERBB2 and cervical cancer: Dysregulation and sustained activation of several RTKs, including VEGFR, HER2/ErbB2, MET, EGFR, and PDGFR, as well as its downstream oncogenic cascades can lead to cervical cancer tumorigenesis, which are associated with poor prognosis and chemoresistance for cervical cancer [34–39].